☆ 4.7 Article

A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo

COMMUNICATIONS BIOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Immunology

Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019 (COVID-19)

Sarju Ganatra et al.

Summary: In this observational analysis, treatment with nirmatrelvir plus ritonavir in nonhospitalized vaccinated patients at high risk of disease progression was associated with a significantly reduced likelihood of emergency room visits, hospitalization, or death between days 10 and 30, with no apparent increase in serious complications.

CLINICAL INFECTIOUS DISEASES (2023)

Add to Collection

Article Medicine, General & Internal

Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large US Health System A Population-Based Cohort Study

Scott Dryden-Peterson et al.

Summary: The EPIC-HR trial showed that nirmatrelvir plus ritonavir significantly reduced hospitalization or death among unvaccinated outpatients with early COVID-19. However, it's uncertain whether this treatment has the same effect on vaccinated populations. This study aimed to assess the risk reduction of nirmatrelvir plus ritonavir in hospitalization or death among outpatients with early COVID-19 who already had SARS-CoV-2 immunity and immune-evasive SARS-CoV-2 lineages.

ANNALS OF INTERNAL MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Jennifer Hammond et al.

Summary: In high-risk, unvaccinated adults, treatment of Covid-19 with nirmatrelvir plus ritonavir can significantly reduce the risk of hospitalization and death, with good safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo

Leo Hanke et al.

Nature Communications (2022)

Add to Collection

Article Immunology

An engineered bispecific human monoclonal antibody against SARS-CoV-2

Zhaohui Li et al.

Summary: The development of a bispecific monoclonal antibody, bsAb15, based on B38 and H4 antibodies, shows improved neutralizing efficiency against SARS-CoV-2 and the ability to neutralize most variants of concern. Animal studies demonstrate the potential of bsAb15 for both prophylactic and therapeutic applications against severe COVID-19.

NATURE IMMUNOLOGY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Recent advances in developing small-molecule inhibitors against SARS-CoV-2

Rong Xiang et al.

Summary: The COVID-19 pandemic has caused chaos worldwide, with vaccines in distribution but treatment methods lagging behind. Researchers are working hard to understand the virus and develop effective treatments.

ACTA PHARMACEUTICA SINICA B (2022)

Add to Collection

Review Cell Biology

Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal

Kunal Nepali et al.

Summary: Unprecedented efforts have been made by researchers to develop vaccine platforms for controlling the COVID-19 pandemic. In addition to vaccination, supplementing therapeutic options with small molecules/peptides and antibodies is seen as a prudent strategy to tackle emerging variants of SARS-CoV-2. Collective efforts have generated a large library of chemically diverse small molecule-based drugs, targeting various proteins involved in viral replication. Accelerated FDA approvals for small molecules in the treatment of COVID-19 are anticipated. However, strategies like detailed preclinical investigations, in-vitro profiling against emerging variants, rapid screening of drug libraries, utilization of machine learning predictive models, and design of antibody-drug conjugates are needed to fully utilize the potential benefits of these small molecules.

JOURNAL OF BIOMEDICAL SCIENCE (2022)

Add to Collection

Article Immunology

Targeting SARS-CoV-2 infection through CAR-T-like bispecific T cell engagers incorporating ACE2

Mikail Dogan et al.

Summary: The study engineered primary CD8 T cells to express SARS-CoV-2 Spike protein-specific CARs and developed ACE2-Bite as a bispecific T cell engager, showing highly specific and potent cytotoxicity. ACE2-Bite also demonstrated higher binding and neutralization affinity to SARS-CoV-2 Delta and Omicron variants.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Wilfredo F. Garcia-Beltran et al.

Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.

CELL (2021)

Add to Collection

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Xuping Xie et al.

Summary: The study found that human sera from recipients of the BNT162b2 vaccine can neutralize SARS-CoV-2 viruses containing key spike mutations from the newly emerged UK and SA variants.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Kai Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Cell Biology

Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms

Yao Sun et al.

CELL RESEARCH (2021)

Add to Collection

Article Multidisciplinary Sciences

Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice

Raoul De Gasparo et al.

Summary: The bispecific IgG1-like molecule CoV-X2 can simultaneously bind two independent sites on the RBD, prevent spike binding to ACE2, neutralize SARS-CoV-2 and its variants, and protect mice from disease in a mouse model of SARS-CoV-2 infection. This demonstrates the feasibility and efficacy of targeting non-overlapping RBD epitopes with IgG-like bispecific antibodies.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Delphine Planas et al.

Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Jianying Liu et al.

Summary: Serum samples from individuals vaccinated with the BNT162b2 vaccine can neutralize various SARS-CoV-2 variants, indicating mass immunization as a central strategy to end the global COVID-19 pandemic.

NATURE (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

Alejandro Jara et al.

Summary: A study in Chile involving 10.2 million participants assessed the effectiveness of an inactivated SARS-CoV-2 vaccine developed in China. Fully immunized individuals had vaccine effectiveness of 65.9% for preventing Covid-19 and 87.5% for preventing hospitalization, 90.3% for preventing ICU admission, and 86.3% for preventing death.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants

Venkata-Viswanadh Edara et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cell Biology

Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern

Hyeseon Cho et al.

Summary: Research isolated 216 monoclonal antibodies from patients with COVID-19, with three potent antibodies neutralizing the Alpha and Beta variants of SARS-CoV-2. Bispecific antibodies designed through distinct mechanisms showed high efficacy in inhibiting virus infection, with one exhibiting over 100-fold higher potency than a monoclonal antibody cocktail and protecting against disease in hamster models.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Microbiology

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes

Takuya Tada et al.

Summary: Convalescent-phase sera and antibodies elicited by Pfizer BNT162b2 vaccination can still neutralize several SARS-CoV-2 variants effectively, while Regeneron monoclonal antibodies may be less effective against certain variants, suggesting the need for continued surveillance for potential new variants.

MBIO (2021)

Add to Collection

Article Multidisciplinary Sciences

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Peng Zhou et al.

NATURE (2020)

Add to Collection

Article Medicine, General & Internal

Clinical Characteristics of Coronavirus Disease 2019 in China

W. Guan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Renhong Yan et al.

SCIENCE (2020)

Add to Collection

Article Microbiology

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Alexander E. Gorbalenya et al.

NATURE MICROBIOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Vanessa Monteil et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Markus Hoffmann et al.

CELL (2020)

Add to Collection

Letter Immunology

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

Xiangyu Chen et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Yan Wu et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

A human monoclonal antibody blocking SARS-CoV-2 infection

Chunyan Wang et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Multidisciplinary Sciences

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

Changhai Lei et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Oncology

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

Zou Xin et al.

FRONTIERS OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Rui Shi et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Cross-neutralization ofSARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto et al.

NATURE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Yunlong Cao et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Xiangyang Chi et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Alina Baum et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2

Kui K. Chan et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2

Anum Glasgow et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Add to Collection

Article Medicine, Research & Experimental

Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic

Kewen Qian et al.

MABS (2020)

Add to Collection

Article Medicine, Research & Experimental

Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody

Karin Staflin et al.

JCI INSIGHT (2020)

Add to Collection

Article Medicine, Research & Experimental

A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy

Xiaoniu Miao et al.

MABS (2020)

Add to Collection

Review Immunology

Antibody therapies for the prevention and treatment of viral infections

Georgina Salazar et al.

NPJ VACCINES (2017)

Add to Collection

Review Immunology

Mesenchymal Stem Cell: Keystone of the Hematopoietic Stem Cell Niche and a Stepping-Stone for Regenerative Medicine

Paul S. Frenette et al.

ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)

Add to Collection

Review Oncology

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

Patrick A. Baeuerle et al.

CANCER RESEARCH (2009)

Add to Collection

Review Immunology

Fc gamma receptors: Old friends and new family members

F Nimmerjahn et al.

IMMUNITY (2006)

Add to Collection

Review Immunology

Cytotoxic T lymphocytes: All roads lead to death

M Barry et al.

NATURE REVIEWS IMMUNOLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.